BioPorto A/S (BIOPOR.CO)

1.2540 -0.0200 (-1.57%) At close: 04:46PM CEST

BioPorto A/S

Tuborg Havnevej 15, st.
Ground Floor
Hellerup 2900
Denmark
45 45 29 00 00
https://bioporto.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 29

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Peter Morch Eriksen B.B.A., BBA	CEO & Director	292k	N/A	1960
Prof. Lars Otto Uttenthal	Chief Scientific Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.

Description

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.

Corporate governance

BioPorto A/S’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.